Cargando…
TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy
Primary central nervous system lymphoma (PCNSL) is an aggressive variant of diffuse large B-cell lymphoma (DLBCL) confined to the CNS. TP53 mutations (MUT-TP53) were investigated in the context of MIR34A/B/C- and DAPK promoter methylation status, and associated with clinical outcomes in PCNSL patien...
Autores principales: | Munch-Petersen, Helga D., Asmar, Fazila, Dimopoulos, Konstantinos, Areškevičiūtė, Aušrinė, Brown, Peter, Girkov, Mia Seremet, Pedersen, Anja, Sjö, Lene D., Heegaard, Steffen, Broholm, Helle, Kristensen, Lasse S., Ralfkiaer, Elisabeth, Grønbæk, Kirsten |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840983/ https://www.ncbi.nlm.nih.gov/pubmed/27101868 http://dx.doi.org/10.1186/s40478-016-0307-6 |
Ejemplares similares
-
Investigation of MGMT and DAPK1 methylation patterns in diffuse large B-cell lymphoma using allelic MSP-pyrosequencing
por: Kristensen, Lasse Sommer, et al.
Publicado: (2013) -
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent manner
por: Dimopoulos, Konstantinos, et al.
Publicado: (2017) -
Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma
por: Kristensen, Lasse Sommer, et al.
Publicado: (2014) -
Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another “double hit” lymphoma with very poor outcome?
por: Asmar, Fazila, et al.
Publicado: (2014) -
Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets
por: Krogh, Nicolai, et al.
Publicado: (2020)